BR0117195A - Métodos para o tratamento ou profilaxia de efeitos patogênicos mediados por aldosterona em um sujeito que usa um epóxi esteroidal antagonista da aldosterona - Google Patents

Métodos para o tratamento ou profilaxia de efeitos patogênicos mediados por aldosterona em um sujeito que usa um epóxi esteroidal antagonista da aldosterona

Info

Publication number
BR0117195A
BR0117195A BR0117195-0A BR0117195A BR0117195A BR 0117195 A BR0117195 A BR 0117195A BR 0117195 A BR0117195 A BR 0117195A BR 0117195 A BR0117195 A BR 0117195A
Authority
BR
Brazil
Prior art keywords
aldosterone
subject
treatment
methods
prophylaxis
Prior art date
Application number
BR0117195-0A
Other languages
English (en)
Inventor
Gordon H Williams
John W Funder
Susan M Garthwaite
Barbara Roniker
Kenton N Fedde
Ricardo Rocha
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0117195A publication Critical patent/BR0117195A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA O TRATAMENTO OU PROFILAXIA DE EFEITOS PATOGêNICOS MEDIADOS POR ALDOSTERONA EM UM SUJEITO QUE USA UM EPóXI ESTEROIDAL ANTAGONISTA DA ALDOSTERONA". A presente invenção fornece métodos para o tratamento ou profilaxia de um ou mais efeitos patogênicos mediados por aldosterona em um sujeito que sofra ou que seja suscetível ao efeito ou aos efeitos patogênicos, em que o sujeito tem uma ou mais condições selecionadas do grupo que consiste de um nível de aldosterona endógena sub-normal, sensibilidade ao sal e uma dieta de elevada ingestão de sódio. Os métodos compreendem administrar ao sujeito uma quantidade terapeuticamente eficaz de um ou mais compostos epóxi esteroidais que são antagonistas da aldosterona.
BR0117195-0A 2001-12-13 2001-12-13 Métodos para o tratamento ou profilaxia de efeitos patogênicos mediados por aldosterona em um sujeito que usa um epóxi esteroidal antagonista da aldosterona BR0117195A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/048419 WO2003051372A1 (en) 2001-12-13 2001-12-13 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist

Publications (1)

Publication Number Publication Date
BR0117195A true BR0117195A (pt) 2005-02-09

Family

ID=21743121

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0117195-0A BR0117195A (pt) 2001-12-13 2001-12-13 Métodos para o tratamento ou profilaxia de efeitos patogênicos mediados por aldosterona em um sujeito que usa um epóxi esteroidal antagonista da aldosterona

Country Status (9)

Country Link
EP (1) EP1453522A1 (pt)
JP (1) JP2005516015A (pt)
KR (1) KR20040071723A (pt)
AU (1) AU2002249804A1 (pt)
BR (1) BR0117195A (pt)
CA (1) CA2469950A1 (pt)
IL (1) IL162393A0 (pt)
MX (1) MXPA04005803A (pt)
WO (1) WO2003051372A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004305066B2 (en) * 2003-12-18 2010-04-01 Abbott Rapid Diagnostics International Unlimited Company Monitoring method and apparatus
US8699429B2 (en) 2007-08-31 2014-04-15 Fujitsu Limited Wireless communication system and wireless communication method
CN102203607A (zh) * 2008-10-31 2011-09-28 B.R.A.H.M.S有限公司 根据对心血管系统的影响将食物和/或饮料和/或饮食和/或营养疗法和/或药物进行分类的方法和测定方法
DE102011012712A1 (de) * 2011-03-01 2012-09-06 Frank Lehmann-Horn Verwendung von Aldosteron-Rezeptor-Antagonisten zur Behandlung von weiblicher sexueller Dysfunktion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects

Also Published As

Publication number Publication date
IL162393A0 (en) 2005-11-20
CA2469950A1 (en) 2003-06-26
JP2005516015A (ja) 2005-06-02
EP1453522A1 (en) 2004-09-08
AU2002249804A1 (en) 2003-06-30
KR20040071723A (ko) 2004-08-12
WO2003051372A1 (en) 2003-06-26
MXPA04005803A (es) 2004-11-01

Similar Documents

Publication Publication Date Title
NO20030955L (no) Fremgangsmåte for behandling av erektil dysfunksjon og ökning av libido hosmenn
MXPA03001859A (es) Metodo para incrementar en la mujer testosterona y concentraciones de esteroides relacionados.
BR0212586A (pt) Composição, uso de uma combinação de ipratrópio ou um sal deste e de xilometazolina ou um sal desta, e, métodos para o tratamento de uma condição selecionada ao grupo que consiste de sintomas associados com o resfriado comum e sintomas associaods com a rinite e para estabilizar uma solução aquosa de ipratrópio ou um sal deste e xilometazolina ou um sal desta
BR0109966A (pt) Combinação de compostos orgânicos
Oh et al. Vitamin D maintains E-cadherin intercellular junctions by downregulating MMP-9 production in human gingival keratinocytes treated by TNF-α
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
BR0300599A (pt) Agentes não-peptìdicos da gnrh, composições farmacêuticas e métodos para o seu uso
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
BRPI0416551A (pt) inibidores da 17beta-hidróxi-esteróide deshidrogenase de tipo i
BR9914419A (pt) Terapia para melhoria da percepção
Lee et al. Ursodeoxycholic acid induces death receptor-mediated apoptosis in prostate cancer cells
Xiao et al. Mechanisms of gallbladder hypomotility in pregnant guinea pigs
Van Erpecum et al. Ursodeoxycholic acid reduces protein levels and nucleation-promoting activity in human gallbladder bile
MA38694B1 (fr) Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase
BR0117195A (pt) Métodos para o tratamento ou profilaxia de efeitos patogênicos mediados por aldosterona em um sujeito que usa um epóxi esteroidal antagonista da aldosterona
Offermans et al. Agonist‐sensitive binding of a photoreactive GTP analog to a G‐protein α‐subunit in membranes of HL‐60 cells
Yang et al. Urinary triclosan in south China adults and implications for human exposure
AR029134A1 (es) Metodos para el tratamiento o profilaxis de efectos patogenicos mediados por la aldosterona en un sujeto usando un antagonista de aldosterona epoxi esteroidal
EA200401210A1 (ru) Андрогенная фармацевтическая композиция и способ для лечения депрессии
BR0308515A (pt) Combinação de um antagonista de receptor de aldosterona com ácido nicotìnico ou um derivado de ácido nicotìnico
Sundkvist et al. Leukotriene C4 (LTC4) does not share a cellular efflux mechanism with cGMP: characterisation of cGMP transport by uptake to inside-out vesicles from human erythrocytes
HRP20041150A2 (en) Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
EA201992826A1 (ru) 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ
Zhang et al. In vitro inhibitory effects of bergenin and norbergenin on bovine adrenal tyrosine hydroxylase
BR0308517A (pt) Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.